Daily single-strength vs. thrice-weekly double-strength trimethoprim/sulfamethoxazole for Pneumocystis jirovecii prophylaxis in kidney transplant recipients: a non-inferiority randomized control trial

Abstract Background Pneumocystis jirovecii pneumonia (PJP) is a significant concern in kidney transplant (KT) recipients, with trimethoprim/sulfamethoxazole (TMP/SMX) as the recommended prophylaxis. However, direct comparisons between daily single-strength (DSS) and thrice-weekly double-strength (TD...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Wittawin Chantapoh, Surasak Kantachuvesiri, Napun Sutharattanapong, Jackrapong Bruminhent
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	BMC 2025-10-01
Reeks:	BMC Infectious Diseases
Onderwerpen:	Kidney transplant Pneumocystis jirovecii pneumonia Trimethoprim/sulfamethoxazole
Online toegang:	https://doi.org/10.1186/s12879-025-11821-6
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!